DE Burlo Group Inc. Has $222,000 Stake in Henry Schein, Inc. (NASDAQ:HSIC)

DE Burlo Group Inc. trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 76.3% in the third quarter, HoldingsChannel reports. The firm owned 3,050 shares of the company’s stock after selling 9,830 shares during the period. DE Burlo Group Inc.’s holdings in Henry Schein were worth $222,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HSIC. Cromwell Holdings LLC increased its holdings in Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after purchasing an additional 170 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Henry Schein during the 2nd quarter valued at $31,000. Beach Investment Counsel Inc. PA acquired a new stake in Henry Schein during the 2nd quarter valued at $37,000. Blue Trust Inc. boosted its position in Henry Schein by 104.2% in the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after buying an additional 475 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Henry Schein by 58.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock valued at $68,000 after buying an additional 346 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at approximately $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the transaction, the chief operating officer now owns 87,706 shares of the company’s stock, valued at $6,577,950. The trade was a 12.25 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $73.73 on Thursday. The company has a market capitalization of $9.19 billion, a PE ratio of 30.34, a PEG ratio of 2.15 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.63. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $70.68 and its 200 day simple moving average is $69.69.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. During the same quarter last year, the business posted $1.32 EPS. The firm’s revenue was up .4% compared to the same quarter last year. On average, research analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current year.

Analyst Ratings Changes

HSIC has been the topic of a number of recent research reports. Robert W. Baird decreased their price objective on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. UBS Group decreased their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Barrington Research restated an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.